Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Mostrar otras versiones (1)

Improving the standard of clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAb) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, David R., Schaefer, Alexandra, Leist, Sarah R., Li, Dapeng, Gully, Kendra, Yount, Boyd, Feng, Joy Y., Bunyan, Elaine, Porter, Danielle P., Cihlar, Tomas, Montgomery, Stephanie A., Haynes, Barton F., Baric, Ralph S., Nussenzweig, Michel C., Sheahan, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852229/
https://www.ncbi.nlm.nih.gov/pubmed/33532765
http://dx.doi.org/10.1101/2021.01.27.428478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852229/
https://www.ncbi.nlm.nih.gov/pubmed/33532765
http://dx.doi.org/10.1101/2021.01.27.428478

Ejemplares similares